Vol. 53 | No. 1 | January-June 2025Back

Open Access

Comparison of 600 mg Versus 300 mg Clopidogrel Loading Dose for Patients With Ischemic Heart Disease: A Meta-Analysis of Randomized Controlled Trials

Gwen R. Marcellana, Emilio Jose Gravador, Rodney Jimenez, Richard Henry Tiongco II
May 2025 DOI 10.69944/pjc.ab9a6e6874

More Info

Gwen R. Marcellana, MD | Emilio Jose Gravador, MD | Rodney Jimenez, MD | Richard Henry Tiongco II, MD

St. Luke's Medical Center, Global City, Taguig City, Philippines

Correspondence:
Dr. Gwen R Marcellana.
St. Luke’s Medical Center, Philippines.
Email: grmarcellana@stlukes.com.ph


DISCLOSURE: None

References
  1. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA [Internet]. 2005;294(10):1224–32. Available from: http://dx.doi.org/10.1001/jama.294.10.1224
  2. Ferguson JJ. Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibrinolytic therapy--CLARITY-TIMI 28. Future Cardiol [Internet]. 2005;1(5):605–10. Available from: http://dx.doi.org/10.2217/14796678.1.5.605
  3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet [Internet]. 2001;358(9281):527–33. Available from: http://dx.doi.org/10.1016/s0140-6736(01)05701-4
  4. Klès P. Results of the CREDO study: AHA Chicago, 18 November 2002. Neth Heart J. 2003;11(2):104–5.
  5. Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, et al. Consensus document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term antiplatelet therapy in patients with coronary artery disease. Eur Heart J Suppl [Internet]. 2018;20(Suppl F):F1–74. Available from: http://dx.doi.org/10.1093/eurheartj/suy019
  6. Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart [Internet]. 2001;85(1):92–3. Available from: http://dx.doi.org/10.1136/heart.85.1.92
  7. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial: Results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation [Internet]. 2005;112(19):2946–50. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.105.559088
  8. Montalescot G, Sideris G, Meuleman C, Bal-Dit-Sollier C, Lellouche N, Steg PG, et al. ALBION Trial Investigators. ALBION Trial Investigators J Am Coll Cardiol. 2006;48:931–8.
  9. Angiolillo DJ, Fernández-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Bañuelos C, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J [Internet]. 2004;25(21):1903–10. Available from: http://dx.doi.org/10.1016/j.ehj.2004.07.036
  10. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study: Results from the ARMYDA-2 (antiplatelet therapy for reduction of MYocardial damage during angioplasty) study. Circulation [Internet]. 2005;111(16):2099–106. Available from: http://dx.doi.org/10.1161/01.CIR.0000161383.06692.D4
  11. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study: Results of the Clopidogrel Loading With Eptifibatide to Arrest the reactivity of Platelets (CLEAR PLATELETS) study. Circulation [Internet]. 2005;111(9):1153–9. Available from: http://dx.doi.org/10.1161/01.CIR.0000157138.02645.11
  12. Wolfram RM, Torguson RL, Hassani S-E, Xue Z, Gevorkian N, Pichard AD, et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol [Internet]. 2006;97(7):984–9. Available from: http://dx.doi.org/10.1016/j.amjcard.2005.10.064
  13. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation [Internet]. 2021;144(22):e368–454. Available from: http://dx.doi.org/10.1161/CIR.0000000000001029
  14. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J [Internet]. 2019;40(2):87–165. Available from: http://dx.doi.org/10.1093/eurheartj/ehy394
  15. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J [Internet]. 2023;44(38):3720–826. Available from: http://dx.doi.org/10.1093/eurheartj/ehad191
  16. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med [Internet]. 2001;345(7):494–502. Available from: http://dx.doi.org/10.1056/NEJMoa010746
  17. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost [Internet]. 2007;5(12):2429–36. Available from: http://dx.doi.org/10.1111/j.1538-7836.2007.02775.x
  18. Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial: Assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation [Internet]. 2010;121(1):43–51. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.109.878017
  19. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med [Internet]. 2010;363(10):930–42. Available from: http://dx.doi.org/10.1056/NEJMoa0909475
  20. Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty Myocardial Infarction) Randomized Study. Journal of the American College of Cardiology. 2011;58(15):1592–9.
  21. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet [Internet]. 2011;377(9784):2193–204. Available from: http://dx.doi.org/10.1016/s0140-6736(11)60764-2
  22. Mangiacapra F, Wijns W, De Luca G, Muller O, Trana C, Ntalianis A, et al. Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry. Catheter Cardiovasc Interv [Internet]. 2010;76(1):70–76. Available from: http://dx.doi.org/10.1002/ccd.22465
  23. Jung J-H, Min P-K, Lee S-H, Sung CW, Choi S, Cho JR, et al. Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). Coron Artery Dis [Internet]. 2009;20(2):150–4. Available from: http://dx.doi.org/10.1097/mca.0b013e3283262de2
  24. Abuzahra M, Pillai M, Caldera A, Hartley WB, Gonzalez R, Bobek J, et al. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. Am J Cardiol [Internet].
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.